1,2-phenylene bis(ethane-2,1-diyl)dimethanesulfonate | 130800-04-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1,2-phenylene bis(ethane-2,1-diyl)dimethanesulfonate
• 英文别名: 1,2-Phenylenebis(ethane-2,1-diyl) dimethanesulfonate；2-[2-(2-methylsulfonyloxyethyl)phenyl]ethyl methanesulfonate
• CAS: 130800-04-3
• 化学式: C₁₂H₁₈O₆S₂
• 分子量: 322.403
• InChiKey: TXDKAPWMTOQLAK-UHFFFAOYSA-N

物化性质

• 沸点：
  552.7±43.0 °C(Predicted)
• 密度：
  1.327±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  20
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  104
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1,2-phenylene bis(ethane-2,1-diyl)dimethanesulfonate 在 硫酸 、 氨 、 硝酸 、 三氟乙酸 作用下， 以 乙腈 为溶剂， 100.0 ℃ 、275.8 kPa 条件下， 反应 3.0h， 生成 7-硝基-2,3,4,5-四氢-1H-苯并[d]氮杂卓
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUNDS AS AXL INHIBITORS
  [FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS D'AXL

  摘要：

  Formula I的化合物及其用途是有效的AXL抑制剂，用于治疗由AXL介导的身体状况。

  公开号：

  WO2015143692A1
• 作为产物：
  描述：

  1,2-苯二乙酸 在 lithium aluminium tetrahydride 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 16.5h， 生成 1,2-phenylene bis(ethane-2,1-diyl)dimethanesulfonate
  参考文献：
  名称：

  作为钾通道调节剂的化合物

  摘要：

  本发明涉及一类作为钾通道调节剂的化合物，其为式(I)化合物或其药学上可接受的盐，所述化合物或其药学上可接受的盐对治疗和预防受钾离子通道的活性影响的疾病和病症有效果。

  公开号：

  CN108250128A

文献信息

• BMP-SIGNAL-INHIBITING COMPOUND
  申请人：RIKEN

  公开号：US20190337926A1

  公开（公告）日：2019-11-07

  The present invention relates to novel and excellent small-molecule-corn pounds that specifically antagonize BMP signal pathways, and these compounds can be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus can be used to treat diseases or pathological symptoms related to BMP signal pathway including inflammation, cardiovascular diseases, hematopoietic diseases, cancer, osteodystrophia, or the like, particularly, fibrodysplasia ossificans progressiva, and the present invention relates to provision of a pharmaceutical and pharmacological agent used for specifically antagonizing the BMP signal pathways and acting on the BMP signal pathways in the prevention and treatment or experimental application since the compounds can be beneficial for regulating cell differentiation and/or cell proliferation.

  本发明涉及一种新颖且优秀的小分子化合物，可以特异性拮抗BMP信号通路，这些化合物可用于调节细胞生长、分化、增殖和凋亡，因此可用于治疗与BMP信号通路相关的疾病或病理症状，包括炎症、心血管疾病、造血系统疾病、癌症、骨发育不良等，特别是纤维性骨化进行性疾病。本发明涉及提供一种用于特异性拮抗BMP信号通路并作用于BMP信号通路的药物和药理剂，用于预防和治疗或实验应用，因为这些化合物有助于调节细胞分化和/或细胞增殖。
• Tetrahydrobenzazepines and their use
  申请人：Braje M. Wilfried

  公开号：US20050137186A1

  公开（公告）日：2005-06-23

  The invention relates to tetrahydrobenzazepines of the general formula I in which the variables Ar, A, B, Y, R 1 and R 2 have the meaninigs indicated in claim 1, as well as the N-oxides of these compounds, the physiologically tolerated acid addition salts of these compounds and the physiologically tolerated acid addition salts of the N-oxides. The invention also relates to a pharmaceutical compositon that comprises at least one tetrahydrobenzazepine compound of the formula I, the physically tolerated acid addition salt of I, the N-oxide of compound of the formula I and/or the physically tolerated acid addition salts of the N-oxides of I, and further to the use of a compound according to the present invention for treating disorders that respond benefically to dopamine D 3 receptor antagonists or dopamine D 3 agonists. The compounds according to the invention are preferably useful for the treatment of disorders of the central nervous system such as schizophrenia and depression and for the treatment of renal function disorders.

  该发明涉及一般式I的四氢苯并氮杂环己烷，其中变量Ar、A、B、Y、R1和R2的含义如权利要求1所示，以及这些化合物的N-氧化物，这些化合物的生理耐受酸盐以及这些化合物的N-氧化物的生理耐受酸盐。该发明还涉及一种制剂，包括至少一种一般式I的四氢苯并氮杂环己烷化合物，一般式I的生理耐受酸盐，一般式I的化合物的N-氧化物和/或一般式I的N-氧化物的生理耐受酸盐，并且还涉及根据本发明用于治疗对多巴胺D3受体拮抗剂或多巴胺D3激动剂有益反应的疾病的化合物的用途。根据本发明的化合物优选用于治疗中枢神经系统疾病，如精神分裂症和抑郁症，以及治疗肾功能障碍。
• FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS
  申请人：Ahmed Gulzar

  公开号：US20090221555A1

  公开（公告）日：2009-09-03

  The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , A 1 , A 2 , A 3 , A 4 , and A 5 , are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供公式I或II化合物或其药学上可接受的盐形式，其中R1、R2、R3、R4、R5、A1、A2、A3、A4和A5如本文所定义。公式I或II化合物具有ALK和/或c-Met抑制活性，可用于治疗增殖性疾病。
• Tetrahydrobenzazepines and their use in the modulation of the dopamine d3 receptor
  申请人：Braje Wilfried

  公开号：US20090105224A1

  公开（公告）日：2009-04-23

  The invention relates to tetrahydrobenzazepines of the general formula I in which the variables Ar, A, B, Y, R 1 and R 2 have the meanings indicated in claim 1, as well as the N-oxides of these compounds, the physiologically tolerated acid addition salts of these compounds and the physiologically tolerated acid addition salts of the N-oxides. The invention also relates to a pharmaceutical composition that comprises at least one tetrahydrobenzazepine compound of the formula I, the physically tolerated acid addition salt of I, the N-oxide of compound of the formula I and/or the physically tolerated acid addition salts of the N-oxides of I, and further to the use of a compound according to the present invention for treating disorders that respond beneficially to dopamine D 3 receptor antagonists or dopamine D 3 agonists. The compounds according to the invention are preferably useful for the treatment of disorders of the central nervous system such as schizophrenia and depression and for the treatment of renal function disorders.

  本发明涉及一般式I的四氢苯并氮平类化合物，其中变量Ar、A、B、Y、R1和R2具有权利要求书中所示的含义，以及这些化合物的N-氧化物、生理耐受酸盐和N-氧化物的生理耐受酸盐。本发明还涉及一种药物组合物，包括至少一种式I的四氢苯并氮平化合物、I的生理耐受酸盐、式I的化合物的N-氧化物和/或I的N-氧化物的生理耐受酸盐，以及根据本发明使用化合物治疗对多巴胺D3受体拮抗剂或多巴胺D3激动剂有益反应的疾病。本发明的化合物通常用于治疗中枢神经系统的疾病，如精神分裂症和抑郁症，以及肾功能障碍的治疗。
• Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors
  申请人：Ahmed Gulzar

  公开号：US20120165519A1

  公开（公告）日：2012-06-28

  The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , A 1 , A 2 , A 3 , A 4 , and A 5 , are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供了式I或II的化合物或其药学上可接受的盐形式，其中R1、R2、R3、R4、R5、A1、A2、A3、A4和A5如本文所定义。式I或II的化合物具有ALK和/或c-Met抑制活性，并可用于治疗增生性疾病。